TOP TEN perturbations for 1064_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1064_at
Selected probe(set): 201745_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1064_at (201745_at) across 6672 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):3.5490208
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.4777613
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

myotonic dystrophy study 4 (deltoid muscle; DM-like) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-2.4830036
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (deltoid muscle; DM-like)
Deltoid muscle biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (biceps brachii; DM2) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-2.4318066
Number of Samples:3 / 3
Experimental myotonic dystrophy study 4 (biceps brachii; DM2)
Biceps brachii biopsies obtained from patients with myotonic dystrophy type 2 (DM2).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (skeletal muscle; DM2) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-2.3710394
Number of Samples:8 / 3
Experimental myotonic dystrophy study 4 (skeletal muscle; DM2)
Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 2 (DM2).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

myotonic dystrophy study 4 (biceps brachii; DM-like) / normal skeletal muscle tisuue (fetal)

Relative Expression (log2-ratio):-2.3186235
Number of Samples:9 / 3
Experimental myotonic dystrophy study 4 (biceps brachii; DM-like)
Biceps brachii biopsies obtained from patients with myotonic-like dystrophy (DMx; DM-like; no DMPK or ZNF9 expansion).
Control normal skeletal muscle tisuue (fetal)
Commercially purchased normal fetal skeletal muscle tissue samples.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.271699
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

Huntington's disease study 16 (batch L) / Parkinson's disease study 32 (IPD)

Relative Expression (log2-ratio):2.2523937
Number of Samples:8 / 205
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control Parkinson's disease study 32 (IPD)
Blood samples obtained from patients with idiopathic Parkinson's disease (IPD). All patients were treated with dopaminergic medication and met United Kingdom Parkinson’s Disease Society Brain Bank Criteria except that positive family history was not regarded as an exclusion criterion. Patients that were suspected of having possible secondary causes for parkinsonism such as use of neuroleptic agents, and patients meeting criteria for atypical PD syndromes and who had SPECT data available that showed scans without evidence of dopaminergic deficits were excluded.

Huntington's disease study 16 (batch L) / control blood sample

Relative Expression (log2-ratio):2.200942
Number of Samples:8 / 231
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control control blood sample
Blood samples obtained from healthy subjects including nonconsanguineous controls from families of patients.

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):2.182808
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.